Australian Marine Biodiversity As A Source Of New Drugs To Control Neurodegenerative Disease

澳大利亚海洋生物多样性是控制神经退行性疾病新药的来源

• 批准号: LP0775547
• 负责人: Prof Robert Capon
• 金额: $ 27.41万
• 依托单位: The University of Queensland
• 依托单位国家: 澳大利亚
• 项目类别: Linkage Projects
• 财政年份: 2007
• 资助国家: 澳大利亚
• 起止时间: 2007-08-08 至 2010-09-30
• 项目状态: 已结题
• 来源: https://dataportal.arc.gov.au/RGS/Web/Grants/LP0775547
• 关键词: Australian; Marine; Biodiversity; Source; New

With the aging of Australia's population the impact of neurodegenerative diseases such as Alzheimer's and Parkinson's is rapidly on the rise. There is an urgent need to develop new and better drugs to treat the symptoms and underlying cause of these debilitating diseases. Historically, the majority of the world's pharmaceuticals have been drawn from biodiversity (ie plants, microbes and animals). As one of the few megabiodiverse nations, Australia is ideally positioned to accelerate and focus the search for drugs from nature. This project will explore an exceptionally promising pool of Australian biodiversity, its marine ecosystems, as a source of inspiration for the development of new drugs to treat neurodegenerative diseases.

随着澳大利亚人口老龄化，阿尔茨海默氏症和帕金森氏症等神经退行性疾病的影响正在迅速上升。迫切需要开发新的、更好的药物来治疗这些令人衰弱的疾病的症状和根本原因。从历史上看，世界上大多数药品都是从生物多样性(即植物、微生物和动物)中提取的。作为为数不多的大型生物多样性国家之一，澳大利亚处于加快和集中从自然中寻找药物的理想地位。该项目将探索澳大利亚极具前景的生物多样性池及其海洋生态系统，作为开发治疗神经退行性疾病的新药的灵感来源。